Skip Therapeutics and Sheba Medical Center to Collaborate for the Development of RNA-based Treatments for Rare Diseases

Summation

  • Skip Therapeutics (“Skip”), developer of a computational platform for design of Antisense Oligonucleotide (ASO) based therapies and Sheba Medical Center (“Sheba”), one of the leading medical centers in the world, announced today that they have entered a collaboration for the development of ASO-based treatments for rare genetic diseases.
  • Under the terms of the agreement, Sheba Medical Center will share with Skip Therapeutics its de-identified patient mutation repository and Skip will provide a bioinformatic assessment of the possibility to use ASOs to circumvent the mutation, restore protein function and constitute a relevant therapeutic path.
  • Dan Dominissini, deputy director of the Center for Cancer Research and director of the Hematology Laboratory at Sheba Medical Center, stated, “We are delighted to collaborate with Skip Therapeutics for the development of cutting edge ASO-based therapies for genetic diseases.

Skip Therapeutics (“Skip”), developer of a computational platform for design of Antisense Oligonucleotide (ASO) based therapies and Sheba Medical Center (“Sheba”), one of the leading medical centers in the world, announced today that they have entered a collaboration for the development of ASO-based treatments for rare genetic diseases.

Under the terms of the agreement, Sheba Medical Center will share with Skip Therapeutics its de-identified patient mutation repository and Skip will provide a bioinformatic assessment of the possibility to use ASOs to circumvent the mutation, restore protein function and constitute a relevant therapeutic path.

Skip Therapeutics employs its proprietary bioinformatic engine to identify the most promising ASO-based molecular strategy for treatment of each patient sub-population based on their specific mutations. Skip’s approach has already identified promising targets for which it is performing in-vitro functionality studies with patient cells in collaboration with leading hospitals and academic institutes around the world.

“We are pleased to enter into a collaboration agreement with the world-renowned Sheba Medical Center for the development of ASO-based treatments for rare genetic diseases. Israel is and will always be at the forefront of innovation and it is our privilege and obligation, especially at times like this, to direct Israel’s ingenuity at developing new treatment options and advancing medicine,” said Ariel Feiglin, PhD, Chief Scientific Officer, Skip Therapeutics. “Thousands of rare genetic disorders affect millions of people worldwide. Most disorders are the result of a mutation in a single gene and have a deterministic genetic cause. However, the small number of patients for each disease has hindered development of dedicated treatments. Recent advancements in RNA-therapeutics offer an expanded molecular toolkit that can be deployed rapidly and at relatively low costs to restore protein function of mutated genes. This presents exciting possibilities of drug development for small patient cohorts and eventually even for single patients. To effectively realize these possibilities, it is necessary to incorporate computational tools in the developmental process, and we believe that our computational approach will enable an effective and rapid development of ASO-based treatments.”

Dr. Dan Dominissini, deputy director of the Center for Cancer Research and director of the Hematology Laboratory at Sheba Medical Center, stated, “We are delighted to collaborate with Skip Therapeutics for the development of cutting edge ASO-based therapies for genetic diseases. Sheba Medical Center is a world-leading center dedicated to incorporating and developing innovative techniques and approaches for the benefit of our patients. Skip Therapeutics’ novel computational engine will enables us not only to determine the most appropriate therapeutic design for a given genetic disease, but also to directly identify treatable patient populations, thereby maximizing efficiency and minimizing costs. We look forward to propelling gene therapy forward as a result of this exciting collaboration.”

About Antisense Oligonucleotide (ASO)

ASOs are short strands of synthetic, chemically modified, RNA sequences that can be designed to intervene in a molecular process called “splicing” which determines the final RNA sequence that will be translated into a protein. ASOs can be used to manipulate the splicing process and restore function of a mutated gene, by promoting exclusion of the mutated region from the final RNA transcript or by restoring normal splicing where it has been lost. This approach has already proved beneficial, among others, for treating Duchenne Muscular Dystrophy, Batten Disease and Spinal Muscular Atrophy.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Northwell Cardiothoracic Programs Have Nation’s Highest Success Rates

5 Northwell Cardiothoracic Programs (Northwell) include: Long Island Jewish Hospital, Lenox Hill Hospital, South Shore University Hospital, Staten Island University Hospital and the Sandra Atlas Bass Heart Hospital at North Shore University Hospital – received three-star ratings in their respective fields – the highest quality rating possible.

COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™

“AI has the potential to augment human learning and improve the accuracy and precision of cancer diagnostics and treatments,” said Dr. C.K. Wang, chief medical officer, COTA. “It is critical that we evaluate these tools against the current standard of care to validate their efficacy and build trust in AI and new technologies.”

AscellaHealth CEO, Dea Belazi, Honored as a 2024 PM360 Elite 100 Winner

Dea Belazi said, "This honor truly belongs to the entire AscellaHealth team in recognition of their expertise, dedication and ongoing work that enables patients with complex, chronic conditions to access specialty pharmaceuticals and novel therapies that enhance clinical outcomes."

By using this website you agree to accept Medical Device News Magazine Privacy Policy